The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death

RT @iamritu: @EGarciaSayan @SNagueh @DermotPhelanMD @purviparwani @ASE360 @JournalASEcho @Kfarooqi @DocStrom @NadeenFaza @boegel_kelly @Dav…

RT @iamritu: @EGarciaSayan @SNagueh @DermotPhelanMD @purviparwani @ASE360 @JournalASEcho @Kfarooqi @DocStrom @NadeenFaza @boegel_kelly @Dav…

RT @iamritu: @EGarciaSayan @SNagueh @DermotPhelanMD @purviparwani @ASE360 @JournalASEcho @Kfarooqi @DocStrom @NadeenFaza @boegel_kelly @Dav…

RT @iamritu: @EGarciaSayan @SNagueh @DermotPhelanMD @purviparwani @ASE360 @JournalASEcho @Kfarooqi @DocStrom @NadeenFaza @boegel_kelly @Dav…

RT @iamritu: @EGarciaSayan @SNagueh @DermotPhelanMD @purviparwani @ASE360 @JournalASEcho @Kfarooqi @DocStrom @NadeenFaza @boegel_kelly @Dav…

@EGarciaSayan @SNagueh @DermotPhelanMD @purviparwani @ASE360 @JournalASEcho @Kfarooqi @DocStrom @NadeenFaza @boegel_kelly @DavidWienerMD @rajdoc2005 @onco_cardiology #WhyCMR 🔑 to see extensive LGE of ≥15% of LV mass 2x⬆️in SCD risk HCM https://t.co/N1YJNT

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @iamritu: @dr_benoy_n_shah @TheBJCA @global_wic @rajdoc2005 @bogdienache @MasriAhmadMD @sado_dan @hannahcvimaging @lynne_w12 @NMerke @RO…

RT @iamritu: @dr_benoy_n_shah @TheBJCA @global_wic @rajdoc2005 @bogdienache @MasriAhmadMD @sado_dan @hannahcvimaging @lynne_w12 @NMerke @RO…

RT @iamritu: @dr_benoy_n_shah @TheBJCA @global_wic @rajdoc2005 @bogdienache @MasriAhmadMD @sado_dan @hannahcvimaging @lynne_w12 @NMerke @RO…

RT @iamritu: @dr_benoy_n_shah @TheBJCA @global_wic @rajdoc2005 @bogdienache @MasriAhmadMD @sado_dan @hannahcvimaging @lynne_w12 @NMerke @RO…

@dr_benoy_n_shah @TheBJCA @global_wic @rajdoc2005 @bogdienache @MasriAhmadMD @sado_dan @hannahcvimaging @lynne_w12 @NMerke @RODRIGOVISCONT1 @mmamas1973 @Hragy @purviparwani @LucySafi @DocStrom @josephselvacmr @SineadHughes19 There is no RCT but observation

@MasriAhmadMD @danilorenzatti @dr_benoy_n_shah @vass_vassiliou @CircAHA @purviparwani @DrMarthaGulati @LopezOpitz @chiarabd @ErinMichos @hvanspall @HEARTinMagnet @cshenoy3 @cardiacpolymath @Doc_Tiger @ohanloncmr @hpatel824 @HanCardiomd @PatrycjaGalazka @Do

@StefanoNistri @MasriAhmadMD @onco_cardiology @jct_ucb @rajdoc2005 @DeeDeeWangMD @JoaoLCavalcante @DocStrom @venkmurthy @ChamsiPash @AmitRPatelMD reclassification in mostly high and low risk clinical scores but small number of “ events” within 5 yrs Some

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @iamritu: #Euroecho site of LGE #whycmr in HCM important but quantity predicts mortality https://t.co/N1YJNSKs9n https://t.co/s84g45Nl…

RT @iamritu: #Euroecho site of LGE #whycmr in HCM important but quantity predicts mortality https://t.co/N1YJNSKs9n https://t.co/s84g45Nl…

#Euroecho site of LGE #whycmr in HCM important but quantity predicts mortality https://t.co/N1YJNSKs9n https://t.co/ia4fCZDtrH

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @TJ_Yeo: Time to update the HCM-SCD risk calculator? #whycmr #suddencardiacdeath #cardiotwitter https://t.co/wHtlROIiS4

Reconsidering our approach?

RT @TJ_Yeo: Time to update the HCM-SCD risk calculator? #whycmr #suddencardiacdeath #cardiotwitter https://t.co/wHtlROIiS4

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

Time to update the HCM-SCD risk calculator? #whycmr #suddencardiacdeath #cardiotwitter

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @danilorenzatti: It is time to integrate LGE on the HCM risk scores! We need new guidelines soon. #whyCMR https://t.co/Br33yuemVZ

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @arh_cardio: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

RT @arh_cardio: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

RT @arh_cardio: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

RT @danilorenzatti: It is time to integrate LGE on the HCM risk scores! We need new guidelines soon. #whyCMR https://t.co/Br33yuemVZ

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @arh_cardio: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

RT @danilorenzatti: It is time to integrate LGE on the HCM risk scores! We need new guidelines soon. #whyCMR https://t.co/Br33yuemVZ

The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death https://t.co/wrOZLCTqKd https://t.co/vmCdNJunAi

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

It is time to integrate LGE on the HCM risk scores! We need new guidelines soon. #whyCMR

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

Interesting study. #LGEmatters

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @journalofCMR: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of pat…

RT @iamritu: For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD score…

For #HCM 🔺AMOUNT of LGE% (0%, 0.1–10%; 10.1–19.9%; ≥ 20%) had greater discriminative power than ACCF/AHA & HCM Risk-SCD scores 🔺Many low-risk by clinical scores (35% for ACCF/AHA & 48% HCM Risk-SCD) had events 🔺Many high-risk by clinical scores h

The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death https://t.co/xlnFWWm58j

RT @LopezOpitz: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

RT @LopezOpitz: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

RT @LopezOpitz: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

RT @DrJTriasDeBes: Como los resultados son muy relevantes y pueden cambiar algunas guías, ningún paciente con MCH sin CRM/LG https://t.co/L…

Como los resultados son muy relevantes y pueden cambiar algunas guías, ningún paciente con MCH sin CRM/LG

RT @LopezOpitz: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

RT @LopezOpitz: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

RT @LopezOpitz: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patie…

The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death | Journal of Cardiovascular Magnetic Resonance | Full Text. 👌🏻 h

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

RT @jpcostabel: Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorit…

Great work by @carlosrochitte et al. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorithm👏👏👏👏 https://t.co/FYOu0QXWdy https://t.co/HbX4sfsuzT

Scar volume on #CMR in HCM a better risk predictor for scd https://t.co/V7ZkYu56Ar

@MasriAhmadMD @DrFuisz @danilorenzatti @Mehtap58194722 @docvikrama @mugander @onco_cardiology @VLSorrellImages @chiarabd @rajdoc2005 @IzgiCemil @afshinfarzan A paper relevant to this thread that was published this week: https://t.co/MjfW6MOtdX

The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic card... - PubMed - NCBI #CMR https://t.co/PcGaq6N2Yq